A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab as a first-line therapy for patients with metastatic colorectal cancer

被引：0
|
作者：
Yasushi Sato
Hiroyuki Ohnuma
Masahiro Hirakawa
Minoru Takahashi
Takahiro Osuga
Yutaka Okagawa
Kazuyuki Murase
Kohichi Takada
Yutaka Kawano
Satoshi Iyama
Tsuyoshi Hayashi
Tsutomu Sato
Koji Miyanishi
Rishu Takimoto
Masayoshi Kobune
Kenji Okita
Toru Mizuguchi
Tomohisa Furuhata
Koichi Hirata
Junji Kato
机构：
[1] Sapporo Medical University School of Medicine,Department of Medical Oncology and Hematology
[2] Sapporo Kyoritsu Gorinbashi Hospital,Division of Gastroenterology
[3] Sapporo Medical University School of Medicine,Department of Surgery, Surgical Oncology and Science
来源：
Cancer Chemotherapy and Pharmacology | 2015年 / 75卷
关键词：
Bevacizumab; Capecitabine; Colorectal cancer; Irinotecan; Oxaliplatin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：587 / 594
页数：7
相关论文
共 50 条
  • [41] Bevacizumab in Combination with Capecitabine plus Irinotecan as First-Line Therapy in Metastatic Colorectal Cancer: A Pooled Analysis of 2 Phase II
    Garcia Alfonso, Pilar
    Munoz Martin, Andres
    Alvarez Suarez, Sonsoles
    Blanco Codeidido, Monserrat
    Mondejar Solis, Rebeca
    Tapia Rico, Gonzalo
    Lopez Martin, Pilar
    Martin, Miguel
    [J]. ONKOLOGIE, 2013, 36 (06): : 363 - 367
  • [42] A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (PTS) with advanced or metastatic colorectal cancer (MCRC)
    Maroun, Jean A.
    Jonker, Derek
    Goel, Rakesh
    Cripps, Christine
    Lister, Diane
    Chiritescu, Gabriela
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [43] Oxaliplatin and Capecitabine (CAPOX) in Non Selected Patients With Metastatic Colorectal Cancer (MCRC) After First-line Irinotecan Based Regimen
    Fonseca, P. J.
    Solis, P.
    Vieitez, J. M.
    Izquierdo, M.
    Pardo, P.
    Gutierrez, E.
    Perez, Q.
    Alvarez, C.
    Frunza, M.
    Uriol, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S422 - S423
  • [44] A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer
    Puthillath, Ajithkumar
    Mashtare, Terry, Jr.
    Wilding, Gregory
    Khushalani, Nikhil
    Steinbrenner, Lynn
    Ross, Mary Ellen
    Romano, Karen
    Wisniewski, Michelle
    Fakih, Marwan G.
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2009, 71 (03) : 242 - 248
  • [45] Phase I/II study of capecitabine(C)/oxaliplatin(O)/ irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
    Ou, K.
    Liu, X.
    Ma, X.
    Gao, L.
    Wang, Q.
    Yang, L.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1514 - S1514
  • [46] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Cabebe, Elwyn C.
    Fisher, George A.
    Sikic, Branimir I.
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (03) : 1082 - 1087
  • [47] A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer
    Elwyn C. Cabebe
    George A. Fisher
    Branimir I. Sikic
    [J]. Investigational New Drugs, 2012, 30 : 1082 - 1087
  • [48] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Bang, Yeong Hak
    Kim, Jeong Eun
    Lee, Ji Sung
    Kim, Sun Young
    Kim, Kyu-Pyo
    Kim, Tae Won
    Hong, Yong Sang
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [49] PHASE II STUDY OF BEVACIZUMAB plus OXALIPLATIN PLUS CAPECITABINE FOLLOWED BY BEVACIZUMAB plus ERLOTINIB AS FIRST-LINE TREATMENT IN METASTATIC COLORECTAL CANCER
    Munoz, A.
    Pericay, C.
    Llorente, B.
    Alonso, V
    Duenas, R.
    Roca, J.
    Rivera, F.
    Falco, E.
    Alvarez, I
    Salud, A.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 73 - 74
  • [50] Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yeong Hak Bang
    Jeong Eun Kim
    Ji Sung Lee
    Sun Young Kim
    Kyu-Pyo Kim
    Tae Won Kim
    Yong Sang Hong
    [J]. Scientific Reports, 11
12345